Regeneron Pharmaceuticals (REGN) Return on Capital Employed (2010 - 2026)
Regeneron Pharmaceuticals' quarterly Return on Capital Employed came in at 10.19% in Q1 2026, down 105.0% year-on-year from 203.85% in Q1 2025, and up 2.54% quarter-over-quarter from 9.94% in Q4 2025.
Regeneron Pharmaceuticals has reported Return on Capital Employed for 17 years, with the latest figure at 10.19% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 105.0% year-over-year to 10.19%; the trailing twelve-month figure through Mar 2026 stood at 10.19% (down 105.0% YoY), and the FY2025 full-year result was 10.28%, down 239.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 10.19%, up from 9.94% in the prior quarter.
- The five-year high for Return on Capital Employed was 39.73% in Q1 2022, with the low at 9.94% in Q4 2025.
- Average Return on Capital Employed over 5 years is 16.26%, with a median of 12.78% recorded in 2024.
- Peak annual rise in Return on Capital Employed reached 1174 bps in 2022, while the deepest fall reached 2466 bps in 2022.
- Tracing REGN's Return on Capital Employed over 5 years: stood at 18.73% in 2022, then decreased by 26 bps to 13.86% in 2023, then declined by 14 bps to 11.86% in 2024, then declined by 16 bps to 9.94% in 2025, then climbed by 3 bps to 10.19% in 2026.
- The last three Return on Capital Employed figures came in at 10.19% (Q1 2026), 9.94% (Q4 2025), and 10.61% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -21.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.19% |
| Dec 31, 2025 | 9.94% |
| Sep 30, 2025 | 10.61% |
| Jun 30, 2025 | 11.23% |
| Mar 31, 2025 | 11.24% |
| Dec 31, 2024 | 11.86% |
| Sep 30, 2024 | 12.00% |
| Jun 30, 2024 | 12.31% |
| Mar 31, 2024 | 12.78% |
| Dec 31, 2023 | 13.86% |
| Sep 30, 2023 | 15.18% |
| Jun 30, 2023 | 15.90% |
| Mar 31, 2023 | 16.68% |
| Dec 31, 2022 | 18.73% |
| Sep 30, 2022 | 25.37% |
| Jun 30, 2022 | 28.87% |
| Mar 31, 2022 | 39.73% |
| Dec 31, 2021 | 43.39% |
| Sep 30, 2021 | 39.62% |
| Jun 30, 2021 | 42.02% |
| Mar 31, 2021 | 27.99% |
| Dec 31, 2020 | 25.68% |
| Sep 30, 2020 | 23.88% |
| Jun 30, 2020 | 24.32% |
| Mar 31, 2020 | 18.37% |
| Dec 31, 2019 | 18.00% |
| Sep 30, 2019 | 19.10% |
| Jun 30, 2019 | 18.94% |
| Mar 31, 2019 | 22.69% |
| Dec 31, 2018 | 25.79% |
| Sep 30, 2018 | 26.28% |
| Jun 30, 2018 | 27.46% |
| Mar 31, 2018 | 28.40% |
| Dec 31, 2017 | 27.37% |
| Sep 30, 2017 | 25.98% |
| Jun 30, 2017 | 24.39% |
| Mar 31, 2017 | 23.52% |
| Dec 31, 2016 | 23.51% |
| Sep 30, 2016 | 21.87% |
| Jun 30, 2016 | 24.39% |
| Mar 31, 2016 | 26.83% |
| Dec 31, 2015 | 27.31% |
| Sep 30, 2015 | 30.78% |
| Jun 30, 2015 | 28.30% |
| Mar 31, 2015 | 27.21% |
| Dec 31, 2014 | 27.30% |
| Sep 30, 2014 | 25.20% |
| Jun 30, 2014 | 28.32% |
| Mar 31, 2014 | 27.91% |
| Dec 31, 2013 | 29.76% |
| Sep 30, 2013 | 30.96% |
| Jun 30, 2013 | 31.05% |
| Mar 31, 2013 | 29.71% |
| Dec 31, 2012 | 26.81% |
| Sep 30, 2012 | 19.31% |
| Jun 30, 2012 | 0.48% |
| Mar 31, 2012 | -12.07% |
| Dec 31, 2011 | -20.41% |
| Sep 30, 2011 | -19.57% |
| Jun 30, 2011 | -15.81% |
| Mar 31, 2011 | -11.30% |
| Dec 31, 2010 | -10.75% |
| Sep 30, 2010 | -16.94% |